Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Fosun Pharma to Supply COVID-19 Vaccine to Hong Kong and Macau
“So far, all data is satisfactory and processes are fast, and we’ve started clinical trials in
According to Fosun Pharma CEO Yifang Wu, Fosun has dosed 72 volunteers in a Phase I trial in
RNA vaccines include an mRNA sequence that produce antigens on coronavirus-infected cells. The antigen is recognized by the immune system which can then fight them.
mRNA vaccines are expected to be safer than traditional vaccines because they do not carry any form of the virus, and they will continue to work even if the vaccine mutates slightly. However, so far, no mRNA has been approved for use, so as a class of anti-infectives, they are not as well known as more common vaccines.
See our other articles on Fosun, Pfizer and BioNTech.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China